Tamar Polonsky to Dyslipidemias
This is a "connection" page, showing publications Tamar Polonsky has written about Dyslipidemias.
Connection Strength
0.726
-
Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy. Am J Cardiol. 2008 Apr 17; 101(8A):27B-35B.
Score: 0.249
-
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026 Apr 28; 153(17):e1154-e1276.
Score: 0.215
-
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026 May 19; 87(19):2624-2757.
Score: 0.215
-
Small dense low-density lipoprotein cholesterol and coronary artery calcification in the Multi-Ethnic Study of Atherosclerosis. Eur J Prev Cardiol. 2024 Jun 03; 31(8):1048-1054.
Score: 0.048